Oxbryta Recall Investigation: Sickle Cell Community Concerned
Shub & Johns launches an investigation into Pfizer after the company voluntarily recalls all lots of the sickle cell disease treatment, Oxbryta (scientifically voxelotor) from all markets. This decision to recall a vital drug for many individuals leaves these consumers open to various health risks. Consumers who have been impacted are encouraged to join our investigation by filling out the attached form.
Oxbryta Recall
Voxelotor, more widely known as Oxbryta, is a treatment for sickle cell disease – a disease that results in white blood cells, commonly used to transport oxygen throughout the body, to become more sticky which results in these blood cells catching onto each other rather than the oxygen necessary to keep bodies healthy and regulated. Oxbryta was approved by the Food & Drug Administration (FDA) for widespread use in 2019 but seemingly there have been many concerns since then.
While Oxbryta was approved in 2019, data continued to be collected, and clinical trials have been ongoing – researchers wanted to gather a better understanding of the already known risks and benefits but seemingly after just five years Pfizer and other researchers may have become aware of additional risks brought about by the use of Oxbryta.
For some patients, Oxbryta was linked to additional pain crises associated with sickle cell disease. It’s believed that the use of Oxbryta was leading to more risks than benefits. Pfizer followed these research results by voluntarily recalling Oxbryta worldwide.
Results of Oxbryta Recall
The Oxbryta recall comes about after some researchers discover that the continued use of the drug may raise risks of life-threatening health issues such as increased chances of vaso-occlusive crises, a common manifestation of sickle cell disease. Patients who were prescribed the drug may be eligible for compensation due to Pfizer’s negligence.
On the other hand, due to the recall of the sickle cell drug, Oxbryta, patients who relied on the drug to treat the disease have become concerned how the withdrawals could affect their health. Some consumers may have already experienced severe health issues within days of being forced to quit the drug. This abrupt halt of Oxbryta can leave consumers with unintended health risks that would not have come about if Pfizer’s drug did not need to be recalled.
Are you a sickle cell disease patient who was prescribed Oxbryta and recently had to quit your use of the drug due to the recall? Let us know! Fill out the attached form and join the Shub & Johns investigation today!
